ZAMBON, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.740
EU - Europa 994
AS - Asia 394
SA - Sud America 19
OC - Oceania 12
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.166
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.731
CN - Cina 309
IT - Italia 305
DE - Germania 170
FI - Finlandia 162
UA - Ucraina 144
GB - Regno Unito 76
SE - Svezia 75
VN - Vietnam 34
IN - India 20
IE - Irlanda 18
AU - Australia 11
FR - Francia 11
NL - Olanda 7
CA - Canada 6
KR - Corea 6
BG - Bulgaria 5
CO - Colombia 5
RO - Romania 5
AR - Argentina 4
BR - Brasile 4
GR - Grecia 4
HK - Hong Kong 4
BE - Belgio 3
EC - Ecuador 3
ID - Indonesia 3
MX - Messico 3
MY - Malesia 3
BD - Bangladesh 2
ES - Italia 2
EU - Europa 2
HR - Croazia 2
IL - Israele 2
IR - Iran 2
JO - Giordania 2
JP - Giappone 2
KE - Kenya 2
PE - Perù 2
RU - Federazione Russa 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BO - Bolivia 1
DK - Danimarca 1
HU - Ungheria 1
IQ - Iraq 1
LA - Repubblica Popolare Democratica del Laos 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
TR - Turchia 1
Totale 8.166
Salva come PNG Salva come JPEG
Città #
Fairfield 1.071
Woodbridge 780
Houston 572
Jacksonville 542
Ann Arbor 496
Ashburn 449
Cambridge 428
Seattle 426
Chandler 391
Wilmington 390
Princeton 216
San Diego 149
Beijing 96
Des Moines 81
Medford 81
Roxbury 74
Padova 71
Helsinki 63
Nanjing 43
Boardman 34
Dong Ket 34
Guangzhou 30
Shenyang 24
Hebei 22
Nanchang 19
Jiaxing 17
Norwalk 17
London 14
Milan 13
Dublin 11
Rome 11
Changsha 10
Redwood City 10
Tianjin 10
Catania 9
Nürnberg 7
Florence 6
Jinan 6
New York 6
Ogden 6
Selvazzano Dentro 6
Tappahannock 6
Borås 5
Kharkiv 5
Arzignano 4
Chioggia 4
Chiswick 4
Envigado 4
Hefei 4
Islington 4
Munich 4
Mykolayiv 4
Paris 4
Phoenix 4
Pune 4
Turin 4
Athens 3
Brisbane 3
Brussels 3
Delhi 3
Detroit 3
Hong Kong 3
Hounslow 3
Isola del Giglio 3
Kilburn 3
Leawood 3
Melbourne 3
Montesilvano Marina 3
New Haven 3
Palermo 3
Procida 3
Quito 3
Rockville 3
Segrate 3
Torre Del Greco 3
Vicenza 3
Zhengzhou 3
Altopascio 2
Amman 2
Baltimore 2
Beiuș 2
Birmingham 2
Bologna 2
Bondeno 2
Breda 2
Buenos Aires 2
Canosa di Puglia 2
Caorso 2
Chicago 2
Civitanova Marche 2
Conselve 2
Ello 2
Ferentino 2
Giugliano in Campania 2
Indiana 2
Kunming 2
Lima 2
Limena 2
Los Angeles 2
Mahbubnagar 2
Totale 6.914
Salva come PNG Salva come JPEG
Nome #
Mappatura Genetica dell' Ipercolesterolemia Familiare: dati preliminari dell'esperienza padovana 137
Atorvastatin Reduces Macrophage Accumulation in Atherosclerotic Plaques. A Comparison of a Nonstatin-Based Regimen in Patients Undergoing Carotid Endarterectomy. 136
SGLT2 Inhibitors and the Diabetic Kidney 136
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy 131
Review article: the metabolic syndrome--a chronic cardiovascular inflammatory condition. 130
Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells 128
Common hepatic lipase gene promoter variant predicts the degree of neointima formation after carotid endarterectomy: impact of plaque composition and lipoprotein phenotype. 125
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia 124
Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R3i) 119
Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key? 119
Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: A flag for non-HDL-C 117
Accuracy of diagnostic criteria for sporadic Creutzfeldt-Jakob disease among rapidly progressive dementia 116
Dyslipidemia of the Plurimetabolic Syndrome and risk of cerebrovascular events 114
Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase mediated changes in LDL density 113
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement 111
The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity 109
Pro-atherogenic postprandial profile: Meal induced changes of lipoprotein sub-fractions and inflammation markers in obese boys 106
LIPOPROTEIN COMPOSITIONAL ABNORMALITIES IN TYPE 1 (INSULIN-DEPENDENT) DIABETIC PATIENTS 102
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential 102
Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease 97
PLASMA TRIGLYCERIDE AND LDL HETEROGENEITY IN FAMILIAL COMBINED HYPERLIPIDEMIA 95
Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins 95
Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol 93
γ-Hydroxybutyric acid-induced psychosis and seizures. 93
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity 93
A common hepatic lipase gene promoter variant determines clinical response to intensive lipid lowering treatment 90
Association between the -514 C to T polymorphism of the hepatic lipase gene promoter and unstable carotid plaque in patients with severe carotid artery stenosis 87
Residual cardiovascular risk in secondary prevention. 86
Reducing vascular risk in the diabetic patient: implications from the FIELD study 86
Lipoprotein abnormalities in well-treated type II diabetic patients. 86
Premature coronary artery disease and apolipoprotein B and apolipoprotein A-I 84
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia 84
Ultrasound, anthropometry and bioimpedance: a comparison in predicting fat deposition in non-alcoholic fatty liver disease. 83
Non-pharmacological control of plasma cholesterol levels. 81
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 81
DIMERIC LIPOPROTEIN LIPASE ACTIVITY IS BOUND TO TRIGLYCERIDE-RICH LIPOPROTEINS IN POSTHEPARIN PLASMA 79
A common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment 78
Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy 78
Genetic Diagnosis of Familial Hypercholesterolaemia: preliminary data from the University of Padua outpatient lipid clinic. 78
The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. 77
Type 2 diabetes patients: profiles, treatment and daily practice 77
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 77
The Multicentre Atorvastatin Plaque Stabilisation (MAPS) Study 73
Effect of Ritonavir on lipids and post-heparin lipase activities in normal subjects 73
The role of fenofibrate in clinical practice. 69
The Plurimetabolic Syndrome: qualitative lipoprotein abnormalities and atherosclerosis 69
The new ACC/AHA guidelines on the treatment of dyslipidemia: cons. 68
Levels and physicochemical properties of lipoprotein subclasses in moderate hypertriglyceridemia. 68
FAMILIAL COMBINED HYPERLIPIDEMIA AND GENETIC RISK FOR ATHEROSCLEROSIS 68
COMPOSITIONAL DIFFERENCES OF LOW DENSITY LIPOPROTEIN (LDL) PARTICLES IN NORMAL SUBJECTS WITH LDL PHENOTYPE A AND LDL PHENOTYPE B 67
Residual macrovascular risk in 2013: what have we learned? 67
Liporpotein distribution and composition during simvastatin treatment in heterozygous FH patients 66
Le basi razionali della terapia delle ipercolesterolemie 66
Statin treatment and carotid plaque composition: A review of clinical studies 65
EFFECT OF HEPATIC LIPASE ON LDL IN NORMAL MALES AND THOSE WITH CORONARY ARTERY DISEASE 64
PARAOXONASE GENOTYPES, LIPOPROTEIN LIPASE ACTIVITY AND HIGH DENSITY LIPOPROTEINS 63
Changes in LDL density across the menopausal transition 63
Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. 63
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. 61
DRUG TREATMENT OF HYPERLIPIDEMIA IN THE ELDERLY: A MULTICENTER DOUBLE BLIND TRIAL WITH PRAVASTATIN AND BEZAFIBRATE 60
Leptin is associated with the size of the apolipoprotein(a) particle in African tribal populations living on fish or vegetarian diet 59
Consenso sobre tratamiento farmacológico de la dislipidemia aterogénica con terapia combinada estatina-fenofibrato 56
Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes 56
Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile 56
Validity of the ATP III diagnostic criteria for the metabolic syndrome in an elderly Italian Caucasian population the Italian longitudinal study on aging 55
Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia 55
PREVENTION OF RAISED LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN A PATIENT WITH HYPERCHOLESTEROLEMIA AND LIPOPROTEIN LIPASE DEFICIENCY 54
Serum lipoprotein profile and APOE genotype in Alzheimer's disease 54
LIPOPROTEIN ABNORMALITIES IN HYPERTRIGLYCERIDEMIC PATIENTS ON LONG-TERM HAEMODIALYSIS 53
THE LIPOPROTEIN METABOLISM IN THE PLURIMETABOLIC SYNDROME 53
TRATTAMENTO DELL'OBESITA' 52
Obesità e dislipidemia 52
LDL density and oxidation are modulated by PON1 promoter genotype in patients with Alzheimer's disease 52
La lipasi epatica influenza il metabolismo lipoproteico nell'uomo con meccanismo indipendente dalla sua attività enzimatica 51
Le linee guida nella prevenzione della cardiopatia ischemica 51
Hepatic lipase: a marker for cardiovascular disease risk and response to therapy 51
Hepatic lipase as a focal point for coronary artery disease regression with lipid lowering therapy 48
Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators. Clinical and Experimental Evidence. 48
LIPOPROTEIN SUB-FRACTION LEVELS AND COMPOSITION IN OBESE SUBJECTS BEFORE AND AFTER GASTROPLASTY 48
Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial 48
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. 47
Lipoprotein classes and coronary disease regression 46
FAMILIAL COMBINED HYPERLIPIDEMIA AND FAMILIAL HYPERTRIGLYCERIDEMIA 46
Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy 46
In vivo evidence for a role hepatic lipase in human apo B containing lipoprotein metabolism, independent of its lipolytic activity 45
A common polymorphism of the hepatic lipase gene as a determinant of LDL particle density and prevalence of macrophages in carotid plaque of patients with cerebrovascular disease 45
FAMILIAL COMBINED HYPERLIPIDEMIA AND FAMILIAL HYPERTRIGLYCERIDEMIA 45
Reducing cholesterol levels to decrease cardiovascular events: The role of new proprotein convertase subtilisin/kexin type 9 inhibitors 45
Relevance of the -514 C to T hepatic lipase gene promoter variant in predicting individual CAD response to intensive lipid-lowering therapy 43
Effects of hypocaloric dietary treatment enriched in oleic acid on LDL and HDL subclass distribution in madly obese women 43
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. 43
Dietary and drug treatment of dyslipidemias 43
OMEGA-3 POLYUNSATURATED FATTY ACIDS SUPPLEMENTATION AND CARDIOVASCULAR OUTCOMES: DO FORMULATION, DOSAGE, AND BASELINE CARDIOVASCULAR RISK MATTER? AN UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS 43
Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast Rice 43
ANALYSIS OF TECHNIQUES TO OBTAIN PLASMA FOR MEASUREMENTS OF LEVELS OF FREE FATTY ACIDS 42
Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. 42
A common polymorphism in the promoter of the hepatic lipase gene significanlty affect hepatic lipase activity, LDL density and HDL2 cholesterol 42
Plasma phospholipid fatty acid composition, lipid oxidation and inflammatory parameters in a population of fishermen 42
USE OF NIACIN AND RESINS IN PATIENTS WITH COMBINED HYPERLIPIDEMIA 40
C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? 39
Totale 7.348
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.593
article - articoli 26.110
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.697
Totale 57.400
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019443 0 0 0 0 0 0 0 0 0 0 240 203
2019/20201.588 236 45 29 161 147 142 132 180 145 137 148 86
2020/20211.452 81 151 80 122 36 98 44 156 211 199 187 87
2021/20221.664 49 229 208 129 54 96 76 169 43 56 175 380
2022/20231.055 272 72 7 97 155 141 6 81 118 13 68 25
2023/2024446 26 68 62 66 37 40 49 24 38 20 16 0
Totale 8.296